Post-Treatment Change in mir92a Levels Predicts AML Prognosis Better than Single Baseline or Post-Treatment Values
Related Experiment Video
Updated: Sep 24, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Background:
Acute myeloid leukemia (AML) is a heterogeneous malignant disorder. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression.
Methods:
The study included 44 adult AML patients diagnosed according the WHO classification criteria. Circulating levels of mir92a were measured at baseline and on the 28th day after induction of treatment. Levels were classified as high (≥ median) or low (< median) expression. Change of mir92a levels was calculated by subtracting the baseline result from the post-treatment result. The study outcomes included achievement of complete remission (CR) at 28 days post-induction, progression free survival (PFS), and overall survival (OS).
Results:
Patients with increased mir92a levels had significantly higher CR rate. They also had significantly lower mortality rate (3.7% versus 88.2%, p < 0.001), longer PFS time, and longer OS time. Cox-hazard regression analysis identified female gender and increased mir92a levels as independent predictors of PFS while only increased mir92a levels were identified as independent predictor of OS.
Conclusions:
Post-treatment change in levels of circulating mir92a can provide better prediction of PFS and OS in AML patients.
